Recent studies have demonstrated the effectiveness of re-engineering FDA-approved tricyclic neuroleptics, particularly small-molecule activators of PP2A (SMAPs), in inducing apoptosis, promoting the dephosphorylation of PP2A targets such as MYC and AKT and suppressing tumor growth in mouse models [20,163]. This evidence concerns the gene AKT1 and neoplasm.